Diabetes Magna Plus™

Educational Resource · OCC Tijuana

Request Evaluation

Evidence Base

Science and Evidence

Educational content on this site is grounded in published guidelines, peer-reviewed clinical trials, regulatory documentation, and program-specific outcomes data.

Last medically reviewed: June 1, 2026 · Educational content only — not medical advice.

Regulatory references

  • U.S. Food & Drug Administration (FDA) — De Novo authorization for the MagDI™ device for creation of a duodeno-ileal anastomosis. FDA authorization addresses the creation of the anastomosis. It does not constitute approval for claims of diabetes remission, weight loss, or other clinical outcomes. FDA De Novo database.
  • GT Metabolic Solutions — manufacturer of MagDI™. Indications, contraindications, and risks are described in the manufacturer's labeling and Instructions for Use. gtmetabolic.com.

Society guidelines

  • ASMBS / IFSO 2022 Indications for Metabolic and Bariatric Surgery — updated criteria expanding consideration of metabolic surgery to selected patients with BMI ≥30 kg/m² and poorly controlled type 2 diabetes. ASMBS resource library.
  • American Diabetes Association — Standards of Care in Diabetes — annual evidence-based guidance covering diagnosis, glycemic targets, pharmacotherapy, and the role of metabolic surgery. Diabetes Care journal.
  • AACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. AACE clinical guidance.

Foundational clinical trials

  • STAMPEDE — Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. N Engl J Med, 2017.
  • ARMMS-T2D — Courcoulas AP et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. JAMA, 2024.
  • DiRECT — Lean MEJ et al. Primary care–led weight management for remission of type 2 diabetes. Lancet, 2018.
  • SURMOUNT-4 / STEP-4 — durability of GLP-1 and dual GIP/GLP-1 therapy after discontinuation.

OCC publications and program outcomes

The Obesity Control Center (OCC) has contributed to the published literature on bariatric and metabolic surgery outcomes over more than 25 years of practice, including a published outcomes review covering more than 19,801 patients. Program-level statistics reflect the OCC cohort and should not be interpreted as guaranteed individual outcomes.

  • OCC published outcomes review — 19,801 patients (program data).
  • Peer-reviewed publications in bariatric and metabolic surgery journals.

How to evaluate medical content

Look for content that cites primary literature, names a medical reviewer, includes the date last reviewed, distinguishes between regulatory authorization and clinical-outcome claims, and discusses risks alongside benefits.

Limitations

This page summarizes selected references for patient education. It is not a systematic review. Treatment decisions should be made with a qualified physician using current, primary clinical evidence.